NICE Rejects CSL Behring’s Hemgenix Gene Therapy for Haemophilia B Drug 


Share post:

London, UK – The National Institute for Health and Care Excellence (NICE) has rejected CSL Behring’s gene therapy, Hemgenix, as a treatment option for severe and moderately severe haemophilia B. 

Despite promising results from the phase 3 HOPE-B trial, where 96% of patients no longer required routine FIX prophylaxis after a single infusion, NICE’s draft decision disappoints the company. Hemgenix had received conditional marketing authorization from the Medicines and Healthcare products Regulatory Agency in early 2023, making it the first gene therapy licensed for haemophilia B in the UK. 

Approximately 2,000 UK patients suffer from this rare bleeding disorder, and the rejection leaves them seeking other treatment options.

The drug gained Worldwide Notice after it was approved by the FDA in November 2022 and has already been administered to patients in the U.S.  The drug will sports an eye-popping $3.5 million per dose price tag, making it the worlds most expensive drug.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related articles

Illinois Fire Drama: Braidwood-Custer Merger Unravels with Resignations, Vandalism

BRAIDWOOD — The community of Custer was rocked by unforeseen turbulence last week following an intergovernmental merger agreement with...

Illinois Family’s Children, Ohio, Missouri Resident Among Victims of Deadly Ammonia Leak

EFFINGHAM, Ill. - An unforeseen disaster unfolded in Effingham County Friday, as a semi-truck carrying anhydrous ammonia crashed near...

Dramatic Rollover Crash on IL Route 113 Halts Traffic

BRAIDWOOD, IL - A severe single-vehicle rollover accident occurred Saturday morning at the junction of W IL Route 113...

Frankfort Woman Confronted in Gunpoint Parking Lot Robbery

FRANKFORT, IL – A local woman faced a chilling encounter last night when she was approached at gunpoint...